back to news

EANS-News: Marinomed Biotech AG / Marinomed announces its intention to launch an Initial Public Offering and listing on the Vienna Stock Exchange


Vienna, 5 November 2018. Vienna-based Marinomed Biotech AG (“Marinomed” or the “company”), an established biopharmaceutical company creating innovative therapies for allergy, respiratory and eye diseases, today announced its intention to raise new funds through an Initial Public Offering of new shares (the “Offering”) with listing of all shares to trading on the official market (Amtlicher Handel) in the prime market segment of the Vienna Stock Exchange.

Company highlights

Established biopharmaceutical company with a global presence

  • Marinomed is a Vienna-based biopharmaceutical company established in 2006. Using its two in-house developed platforms, the technology platform Marinosolv® and the OTC platform Carragelose®, Marinomed has built a significant pipeline with multiple, derisked and near-to-market products.
  • Marinomed also already has strong experience in bringing products to the market with currently six different Carragelose® products successfully marketed to treat viral infections of the respiratory tract.
  • Marinomed has achieved a lean, “asset light” business model in tandem with strong growth by outsourcing the cost intensive components of the value chain. The company’s products are manufactured and sold via partners and licenses in over 30 countries. This approach enables the company to maintain the focus on its main strength: the generation of IP and development of commercial products.

Marinosolv®: an innovative drug delivery platform focused on allergy and eye diseases

  • In 2015, Marinomed succeeded in creating a technology platform that improves the stable solubility in aqueous formulations of hardly soluble compounds (from 10 to over 1,000 times). The Marinosolv® platform thus can achieve products with better bioavailability, especially for the treatment of sensitive tissues such as eyes and nose. This allows a dose reduction, a faster onset of action and less active pharmaceutical ingredient (“API”) in the rest of the body, which can reduce possible side effects. In addition, Marinosolv® allows the production of preservative free products with lower production costs. Products currently developed through the Marinosolv® platform are highly derisked as these are well-known, safe and effective APIs.
  • The platform’s lead product is Budesolv, a solubilized version of corticosteroid budesonide, currently in a pivotal phase III clinical trial for the treatment of allergic rhinitis. Phase III results are expected to be available at the end of Q2 2019 and market launch of Budesolv could already take place in 2021, proving the potential of the Marinosolv® platform and giving Marinomed access to a multi-billion dollar market with a strong growth outlook.
  • The second Marinosolv® derived product in the pipeline is Tacrosolv, a solubilized version of immunosuppressant Tacrolimus, which will be entering phase II clinical trials in 2019 for the treatment of allergic conjunctivitis and will subsequently be investigated in Phase III pivotal trials for allergic conjunctivitis and dry eye syndrome, two well-known blockbuster indications.
  • The Marinosolv® platform has large potential for many other indications through proprietary programs and/or Pharma licensing deals, as 40% of approved drugs and nearly 90% of molecules currently in the discovery pipeline are poorly water-soluble 1).

Carragelose®: a powerful OTC platform focused on respiratory diseases

  • Carragelose® is based on a natural red algae compound that forms a protective layer in the nose and is clinically proven in four clinical trials to be active against more than 200 different respiratory viral strains.
  • The Carragelose® platform has already generated six different products to treat viral infections of the respiratory tract, which are sold globally via established partners and which have generated approx. EUR28m-EUR43m in retail sales in >30 countries in 2017. The use of the nasal and throat sprays as well as the lozenges based on Carragelose® in case of viral infection of the respiratory tract may reduce viral load by up to 99%.
  • Marinomed is thus well positioned in a fast-growing segment of the OTC market (market for non-prescription drugs). The cough, cold and allergy (CCA) market, the target market for the Carragelose® portfolio, is currently worth USD 28bn and is expected to grow by 5% annually (CAGR) until 2027 to USD 36bn 2). Carragelose® has significant growth potential through the development of new products (such as a decongestant nasal spray which combines Carragelose® with Xylometazoline), upcoming near term (new) products launches in major markets and a higher level of market penetration in existing markets.

Experienced leadership team backed by high quality boards

  • Marinomed is led by an experienced management team with strong expertise in virology and infectious diseases, allergies, immunology and molecular biology. The team, headed by CEO Andreas Grassauer, CFO Pascal Schmidt and CSO Eva Prieschl-Grassauer has an extensive background in product development in pharmaceutical companies.
  • The management team is supported by an experienced Supervisory Board and an internationally renowned Scientific Advisory Board, including Prof. Ron Eccles, Prof. Bala Ambati, Prof. Talin Barisani, Prof. Julian Crane and Prof. Marco Idzko.
  • Marinomed has raised over EUR30m in total equity and non-dilutive funding to date.

Dr Andreas Grassauer, Chief Executive Officer of Marinomed, commented:
“Marinomed´s research is focused on the development of pioneering platforms for new and superior therapies to treat respiratory and ophthalmic disorders. With our innovative Marinosolv® technology platform we are planning to enter the multi-billion dollar markets for treatments of allergies and eye diseases. The products of our Carragelose® platform have proven their worth worldwide as first causative treatment against common cold and flu-like illnesses. We will expand this platform further. With the intended listing, we will pursue our success story: An IPO could provide us with the strategic and financial flexibility that we need to successfully commercialize products to treat diseases with unmet medical needs based on our platforms and to further strengthen our position in extremely attractive growth markets.”

Details of the planned Offering

The Offering is subject to market conditions and the approval of the prospectus by the Austrian Financial Market Authority (FMA). The price range for the new shares as well as other details of the Offering will be published in the prospectus before commencement of the offer period of the Offering. The Offering is expected to consist of (i) a public offering to retail and institutional investors in Austria, (ii) a private placement outside Austria to selected institutional investors, including a private placement within the United States to qualified institutional buyers in reliance on Rule 144A under the US Securities Act of 1933, as amended, and (iii) a private placement outside of the United States to certain other eligible institutional investors in reliance on Regulation S under the US Securities Act of 1933, as amended. The Offering will consist exclusively of new bearer shares of Marinomed.

The planned listing on the Vienna Stock Exchange is intended to allow Marinomed to continue its success story using the strategic and financial flexibility available to a listed stock company. The proceeds of an IPO are envisaged to be used for funding the pivotal phase III study of Budesolv, phase II and phase III studies of Tacrosolv as well as the extension of the Marinosolv® technology for additional indications (e.g. lung). Next to that, the proceeds will also be used for broadening the Carragelose® product portfolio (in particular by launch of the decongestant product line), increasing Carragelose® brand awareness, co-fund additional clinical studies for Carragelose® (e.g. for marketing authorization in the US) as well as general corporate purposes such as establishing a cost-effective supply chain for low price markets and repayment of debt.

Erste Group and Kempen are acting as Joint Global Coordinators and Joint Bookrunners. goetzpartners securities functions as Co-Lead Manager.

About Marinomed Biotech AG

Marinomed Biotech AG is a Vienna based biopharmaceutical company focusing on the development of innovative products derived from patent protected technology platforms to treat respiratory and ophthalmic conditions. The Carragelose® platform comprises innovative patent protected products targeting viral infections of the respiratory tract. Carragelose® is used in nasal sprays, throat sprays and lozenges, which are sold in more than 30 countries around the world in collaboration with international partners. The Marinosolv® technology platform increases the efficacy of hardly soluble compounds for the treatment of sensitive tissues such as the eyes and nose. Further information is available at [].

1) Source: Acta Pharmaceutica Sinica B, September 2015 issue
2) Source: Nicholas Hall OTC Yearbook 2018


This press release and the information contained herein are for information purposes only and do neither constitute an offer to sell nor a solicitation of an offer to buy any securities in the United States, Australia, Canada, Japan or in any other jurisdiction. Any securities referred to herein have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”), or the laws of any state of the United States, and may not be offered, sold or otherwise transferred in the United States absent registration or an exemption from registration under the Securities Act. There will be no public offering of the securities in the United States of America, Canada, Japan or Australia.
Any public offer of securities of Marinomed Biotech AG will be made solely in Austria and by means of, and on the basis of, a prospectus (including any supplements thereto, if any) to be approved by the Austrian Financial Market Authority (FMA) and to be published in accordance with Austrian law. An investment decision regarding any publicly offered securities of Marinomed Biotech AG should only be made on the basis of a prospectus. Any orders relating to securities of Marinomed Biotech AG received prior to the commencement of a public offer, if any, will be rejected. If a public offer is to be made in Austria, Marinomed Biotech AG will promptly publish a prospectus upon approval by the FMA by in accordance with the Austrian Capital Markets Act. Following an approval, such approved prospectus will be available free of charge from Marinomed Biotech AG at its registered address at Veterinärplatz 1, A-1210 Vienna, during usual business hours, or on the Marinomed Biotech AG website. Erste Group Bank AG and Kempen & Co N.V (collectively, “Joint Global Coordinators”) are acting exclusively for Marinomed Biotech AG and no-one else in connection with any offering of securities of Marinomed Biotech AG. They will not regard any other person as their respective client in relation to any offering of securities and will not be responsible to anyone other than Marinomed Biotech AG for providing the protections afforded to their respective clients, nor for providing advice in relation to the offering, the contents of this press release or any other matter referred to herein.
This press release contains forward-looking statements, which are based on current views, expectations and projections of the management of Marinomed Biotech AG about future events. These forward-looking statements are subject to risks, uncertainties and assumptions that could cause actual results, performance or events to differ materially from those described in, or expressed or implied by, such statements. The current views, expectations and projections of the management of Marinomed Biotech AG may be identified by the context of such statements or words such as “anticipate,” “believe”, “estimate”, “expect”, “intend”, “plan”, “project” and “target”. Forward-looking statements speak only as of the date they are made and Marinomed Biotech AG does not assume any obligation to update, review or revise any forward-looking statement contained in this press release whether as a result of new information, future developments or otherwise.

end of announcement euro adhoc

issuer: Marinomed Biotech AG
Veterinärplatz 1
A-1210 Wien
phone: 0043250774460
FAX: 0043250774493
ISIN: AT0000A1WD52
stockmarkets: Wien
language: English

Digital press kit:

Rückfragen & Kontakt:

Eva Prieschl-Grassauer, PhD
Chief Scientific Officer, Marinomed
Veterinärplatz 1, 1210 Vienna, Austria
Tel.: +43 (0)1 250 77 4460

Roland Mayrl
Managing Partner, Metrum Communications
Prinz-Eugen-Straße 80/16, 1040 Vienna, Austria
Tel.: +43 (0) 1 504 69 87 331